Cold tumors: a therapeutic challenge for immunotherapy P Bonaventura, T Shekarian, V Alcazer, J Valladeau-Guilemond, ... Frontiers in immunology 10, 168, 2019 | 922 | 2019 |
Zinc and its role in immunity and inflammation P Bonaventura, G Benedetti, F Albarède, P Miossec Autoimmunity reviews 14 (4), 277-285, 2015 | 785 | 2015 |
Medical applications of Cu, Zn, and S isotope effects F Albarede, P Télouk, V Balter, VP Bondanese, E Albalat, P Oger, ... Metallomics 8 (10), 1056-1070, 2016 | 80 | 2016 |
Human endogenous retroviruses (HERVs): shaping the innate immune response in cancers V Alcazer, P Bonaventura, S Depil Cancers 12 (3), 610, 2020 | 54 | 2020 |
Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy P Bonaventura, V Alcazer, V Mutez, L Tonon, J Martin, N Chuvin, E Michel, ... Science Advances 8 (4), eabj3671, 2022 | 45 | 2022 |
Differential effects of TNF-α and IL-1β on the control of metal metabolism and cadmium-induced cell death in chronic inflammation P Bonaventura, A Lamboux, F Albarede, P Miossec PLoS One 13 (5), e0196285, 2018 | 36 | 2018 |
A feedback loop between inflammation and Zn uptake P Bonaventura, A Lamboux, F Albarede, P Miossec PLoS One 11 (2), e0147146, 2016 | 33 | 2016 |
Protective effect of low dose intra-articular cadmium on inflammation and joint destruction in arthritis P Bonaventura, G Courbon, A Lamboux, F Lavocat, H Marotte, F Albarède, ... Scientific reports 7 (1), 2415, 2017 | 29 | 2017 |
Neoepitopes-based vaccines: challenges and perspectives V Alcazer, P Bonaventura, L Tonon, S Wittmann, C Caux, S Depil European Journal of Cancer 108, 55-60, 2019 | 26 | 2019 |
Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019; 10: 168 P Bonaventura, T Shekarian, V Alcazer, J Valladeau-Guilemond, ... Epub 2019/02/26. https://doi. org/10.3389/fimmu. 2019.00168 PMID: 30800125, 2019 | 23 | 2019 |
IL-17A and TNF-α increase the expression of the antiapoptotic adhesion molecule amigo-2 in arthritis synoviocytes G Benedetti, P Bonaventura, F Lavocat, P Miossec Frontiers in Immunology 7, 196070, 2016 | 21 | 2016 |
Regulatory effects of zinc on cadmium-induced cytotoxicity in chronic inflammation P Bonaventura, A Lamboux, F Albarède, P Miossec PLoS One 12 (7), e0180879, 2017 | 18 | 2017 |
HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy V Alcazer, P Bonaventura, L Tonon, E Michel, V Mutez, C Fabres, ... American Journal of Hematology 97 (9), 1200-1214, 2022 | 9 | 2022 |
Cancer vaccines: what’s next? S Depil, P Bonaventura, V Alcazer Oncotarget 10 (40), 3985, 2019 | 4 | 2019 |
Tumour burden and antigen-specific T cell magnitude represent major parameters for clinical response to cancer vaccine and TCR-engineered T cell therapy M Mallet, RE Boulos, V Alcazer, P Bonaventura, Y Estornes, N Chuvin, ... European Journal of Cancer 171, 96-105, 2022 | 3 | 2022 |
Nouvelles approches vaccinales en cancérologie S Depil, P Bonaventura, V Alcazer, L Tonon Bulletin du Cancer 105, S113-S120, 2018 | 1 | 2018 |
Changement de l’homéostasie du Zinc et du Cadmium par l’inflammation chronique et nouvelles options thérapeutiques pour le traitement de l’arthrite P Bonaventura Lyon, 2016 | 1 | 2016 |
Human Endogenous Retroviruses represent a source of shared tumor epitopes inducing high-avidity cytotoxic T cells for cancer immunotherapy. P Bonaventura, V Alcazer, V Mutez, L Tonon, J Martin, N Chuvin, E Michel, ... CANCER IMMUNOLOGY RESEARCH 10 (12), 2022 | | 2022 |
Abstract B49: Human Endogenous Retroviruses represent a source of shared tumor epitopes inducing high-avidity cytotoxic T cells for cancer immunotherapy P Bonaventura, V Alcazer, V Mutez, L Tonon, J Martin, N Chuvin, E Michel, ... Cancer Immunology Research 10 (12_Supplement), B49-B49, 2022 | | 2022 |
IDENTIFICATION OF SHARED TUMOR EPITOPES FROM ENDOGENOUS RETROVIRUSES INDUCING HIGH AVIDITY CYTOTOXIC T CELLS FOR CANCER IMMUNOTHERAPY P Bonaventura, V Alcazer, V Mutez, L Tonon, J Martin, N Chuvin, ... JOURNAL FOR IMMUNOTHERAPY OF CANCER 9, A719-A719, 2021 | | 2021 |